Ustekinumab beats placebo for ulcerative colitis
International trial showed subcutaneous maintenance therapy to be effective
1st October 2019
By Clare Pain
Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.
In the pharma-company funded trial (known as UNIFI), 961 patients from 244 international sites were randomised to one of two different intravenous doses of a single, induction infusion of the drug or IV placebo.
Eight weeks later, clinical remission was achieved in 15.5% of those who had a 130mg dose of ustekinumab, in 15.6% of